Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist.

Gattone VH 2nd, Wang X, Harris PC, Torres VE.

Nat Med. 2003 Oct;9(10):1323-6. Epub 2003 Sep 21.

PMID:
14502283
2.

Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.

Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd.

Nat Med. 2004 Apr;10(4):363-4. Epub 2004 Feb 29.

PMID:
14991049
3.
4.

Do vasopressin receptor type 2 antagonists have therapeutic potential in polycystic kidney diseases?

Doggrell SA.

Expert Opin Investig Drugs. 2004 Apr;13(4):431-4. Review.

PMID:
15102592
5.

Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.

Wang X, Gattone V 2nd, Harris PC, Torres VE.

J Am Soc Nephrol. 2005 Apr;16(4):846-51. Epub 2005 Feb 23.

6.

Role of vasopressin antagonists.

Torres VE.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1212-8. doi: 10.2215/CJN.05281107. Epub 2008 Apr 23. Review.

7.

Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.

Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T.

Cardiovasc Drug Rev. 2007 Spring;25(1):1-13. Review.

PMID:
17445084
8.

Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.

Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF.

Gastroenterology. 2007 Mar;132(3):1104-16. Epub 2006 Dec 20.

PMID:
17383431
9.

PKD1 haploinsufficiency causes a syndrome of inappropriate antidiuresis in mice.

Ahrabi AK, Terryn S, Valenti G, Caron N, Serradeil-Le Gal C, Raufaste D, Nielsen S, Horie S, Verbavatz JM, Devuyst O.

J Am Soc Nephrol. 2007 Jun;18(6):1740-53. Epub 2007 May 2.

10.

Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease.

Yamaguchi T, Nagao S, Kasahara M, Takahashi H, Grantham JJ.

Am J Kidney Dis. 1997 Nov;30(5):703-9.

PMID:
9370187
11.

Acute renal response to the non-peptide vasopressin V2-receptor antagonist SR 121463B in anesthetized rats.

Huang DY, Pfaff I, Serradeil-Le Gal C, Vallon V.

Naunyn Schmiedebergs Arch Pharmacol. 2000 Sep;362(3):201-7.

PMID:
10997721
12.

Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats.

Sabbatini M, Russo L, Cappellaio F, Troncone G, Bellevicine C, De Falco V, Buonocore P, Riccio E, Bisesti V, Federico S, Pisani A.

Am J Physiol Renal Physiol. 2014 May 15;306(10):F1243-50. doi: 10.1152/ajprenal.00694.2013. Epub 2014 Mar 19.

PMID:
24647711
13.

Effects of hydration in rats and mice with polycystic kidney disease.

Hopp K, Wang X, Ye H, Irazabal MV, Harris PC, Torres VE.

Am J Physiol Renal Physiol. 2015 Feb 1;308(3):F261-6. doi: 10.1152/ajprenal.00345.2014. Epub 2014 Dec 10.

14.

Therapies to slow polycystic kidney disease.

Torres VE.

Nephron Exp Nephrol. 2004;98(1):e1-7. Review.

PMID:
15361692
15.

Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats.

Torres VE, Sweeney WE Jr, Wang X, Qian Q, Harris PC, Frost P, Avner ED.

Kidney Int. 2004 Nov;66(5):1766-73.

16.

mTOR signaling in polycystic kidney disease.

Ibraghimov-Beskrovnaya O, Natoli TA.

Trends Mol Med. 2011 Nov;17(11):625-33. doi: 10.1016/j.molmed.2011.06.003. Epub 2011 Jul 19. Review.

PMID:
21775207
17.

Vasopressin directly regulates cyst growth in polycystic kidney disease.

Wang X, Wu Y, Ward CJ, Harris PC, Torres VE.

J Am Soc Nephrol. 2008 Jan;19(1):102-8. Epub 2007 Nov 21.

18.

Mechanisms of Disease: autosomal dominant and recessive polycystic kidney diseases.

Torres VE, Harris PC.

Nat Clin Pract Nephrol. 2006 Jan;2(1):40-55; quiz 55. Review.

PMID:
16932388
19.

Aquaretic agents: what's beyond the treatment of hyponatremia?

Bolignano D, Coppolino G, Criseo M, Campo S, Romeo A, Buemi M.

Curr Pharm Des. 2007;13(8):865-71. Review.

PMID:
17430186
20.

Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury.

Aihara M, Fujiki H, Mizuguchi H, Hattori K, Ohmoto K, Ishikawa M, Nagano K, Yamamura Y.

J Pharmacol Exp Ther. 2014 May;349(2):258-67. doi: 10.1124/jpet.114.213256. Epub 2014 Feb 25.

Supplemental Content

Support Center